Skip to main content
main-content

11-01-2021 | Dapagliflozin | Commentary | Video

PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status

share
SHARE

Mikhail Kosiborod outlines the findings from the PRESERVED-HF trial, demonstrating that dapagliflozin improves symptoms and physical function in people with heart failure with preserved ejection fraction, and discusses the promise of SGLT2 inhibitors for meeting the treatment goals in this population (9:35). 

00:00 Introduction
02:12 Key findings from PRESEVED-HF
04:42 How dapagliflozin compares with other HFpEF medications
07:08 Conclusions so far on SGLT2 inhibitors in HFpEF